Showing 1 - 5 results of 5 for search 'Mikkael A Sekeres', query time: 0.02s Refine Results
  1. 1
    Measurable residual disease in hematologic malignancies: a biomarker in search of a standard

    Measurable residual disease in hematologic malignancies: a biomarker in search of a standard by Namrata S. Chandhok, Mikkael A. Sekeres

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3–internal tandem duplications in the QuANTUM-First trial

    Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3–internal tandem duplications in... by Richard F. Schlenk, Pau Montesinos, Hee-Je Kim, Antonio Romero-Aguilar, Radovan Vrhovac, Elżbieta Patkowska, Pavel Žak, Po-Nan Wang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Herve Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, Harry P. Erba

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review.

    Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. by Yaping Chang, Gordon H Guyatt, Trevor Teich, Jamie L Dawdy, Shaneela Shahid, Jessica K Altman, Richard M Stone, Mikkael A Sekeres, Sudipto Mukherjee, Thomas W LeBlanc, Gregory A Abel, Christopher S Hourigan, Mark R Litzow, Laura C Michaelis, Shabbir M H Alibhai, Pinkal Desai, Rena Buckstein, Janet MacEachern, Romina Brignardello-Petersen

    Published 2021-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Advancing drug development in myelodysplastic syndromes

    Advancing drug development in myelodysplastic syndromes by Alain Mina, Kathy L. McGraw, Lea Cunningham, Nina Kim, Emily Y. Jen, Katherine R. Calvo, Lori A. Ehrlich, Peter D. Aplan, Guillermo Garcia-Manero, James M. Foran, Jacqueline S. Garcia, Amer M. Zeidan, Amy E. DeZern, Rami Komrokji, Mikkael A. Sekeres, Bart Scott, Rena Buckstein, Sara Tinsley-Vance, Amit Verma, Tanya Wroblewski, Steven Pavletic, Kelly Norsworthy

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML

    Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML by David A. Sallman, Rami S. Komrokji, Amy E. Dezern, Marie Sebert, Guillermo Garcia‐Manero, Ramy Rahmé, Eric S. Winer, Jacqueline Lehmann‐Che, Gail J. Roboz, Isabelle Madelaine, Mikkael A. Sekeres, Pierre Peterlin, Onyee Chan, Odile Beyne‐Rauzy, Andrew Kuykendall, Christian Recher, Amy McLemore, Aspasia Stamatoullas, Ling Zhang, Lise Willems, Qianxing Mo, Emmanuel Raffoux, Lisa Nardelli, Céline Berthon, Najla H. Al Ali, Bruno Quesnel, Eric Padron, Hagop M. Kantarjian, Alan F. List, Lionel Ades, Jeffrey E. Lancet, Pierre Fenaux, Thomas Cluzeau

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: